Home Featured Page 90

Featured

Latest

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Navigating Your Psychedelic Career: Networking, Community, and Self-Care

Ibogaine Revealed: Unpacking Kentucky’s Vote on Transformative Drug Treatment Opportunity

Real Harm Reduction Requires Redistribution of Wealth

PT455 – Psychedelics and Success: Conscious Leadership and Investing in Yourself

Colorado DOR Natural Medicine Division Listening Sessions: Part 1

PT454 – The Shadow Aspects of the Psychedelic Movement: Is the...

PT453 – Neuroplasticity, Individualized Integration, and Psychedelic Medicine – Israel 2023

Harmonizing the Mind and Body: Exploring Psychedelics and the Gut-Brain Axis

Psychedelic Law Landscapes: Navigating Decriminalization and Regulatory Reforms

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Psychedelic Bulletin #X

Navigating Your Psychedelic Career: Networking, Community, and Self-Care

Ibogaine Revealed: Unpacking Kentucky’s Vote on Transformative Drug Treatment Opportunity

Real Harm Reduction Requires Redistribution of Wealth

PT455 – Psychedelics and Success: Conscious Leadership and Investing in Yourself

Colorado DOR Natural Medicine Division Listening Sessions: Part 1

PT454 – The Shadow Aspects of the Psychedelic Movement: Is the...

PT453 – Neuroplasticity, Individualized Integration, and Psychedelic Medicine – Israel 2023

Harmonizing the Mind and Body: Exploring Psychedelics and the Gut-Brain Axis

Psychedelic Law Landscapes: Navigating Decriminalization and Regulatory Reforms

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY